Impact Factor 2021: 3.041 (@Clarivate Analytics)
5-Year Impact Factor: 2.776 (@Clarivate Analytics)
Impact Factor Rank: 10/24, Q2 (Tropical Medicine)
  • Users Online: 1215
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 15  |  Issue : 8  |  Page : 361-366

Interleukin-15 is a significant predictor of sarcopenia in human immunodeficiency virus infected patients on antiretroviral therapy: A cross-sectional study


1 Internal Medicine Education Program, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia
2 Tropical Infectious Disease Division, Department of Internal Medicine, Sanglah General Hospital, Denpasar, Bali, Indonesia
3 Geriatric Division, Department of Internal Medicine, Sanglah General Hospital, Denpasar, Bali, Indonesia

Correspondence Address:
Aprianta Agus
Internal Medicine Education Program, Faculty of Medicine, Udayana University, Denpasar, Bali
Indonesia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1995-7645.354418

Rights and Permissions

Objective: To identify the relationship between interleukin (IL)-15 levels and sarcopenia in human immunodeficiency virus (HIV)- infected patients who have received antiretroviral therapy. Methods: This study was a cross-sectional design with 70 participants conducted from January to March 2021. All the participants were assessed for sarcopenia and the IL-15 levels. Sarcopenia was established based on the the Asian Working Group for Sarcopenia (AWGS) 2019 criteria. Plasma IL-15 was determined. This analysis was carried out by means of 2×2 tabulation and the statistical test used is Chi-square. Results: Seventy patients received antiretroviral therapy >6 months and showed a good clinical response. Among them, 36 (51.4%) took zidovudine-based antiretroviral therapy with a median duration of illness of 5 years. The proportion of sarcopenia in patients with HIV infection was 32.9%. The median CD4 cell count was 395.5 cells/L (range: 203-937 cells/L). Logistic regression analysis revealed that age>50 years (aOR 8.3, 95% CI 1.6-44.5), underweight (aOR 7.7, 95% CI 1.5-40.5), IL-15≥150.5 ng/L (aOR 4.9, 95% CI 1.3-19.0) and female (aOR 4.8, 95% CI 1.2-18.3 were significant and independent adverse predictors of sarcopenia in subjects with HIV infection. Conclusions: There is an association between high levels of IL-15 and sarcopenia in HIV-infected patients on antiretroviral therapy for more than 6 months with good clinical response.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed430    
    Printed12    
    Emailed0    
    PDF Downloaded70    
    Comments [Add]    

Recommend this journal